| Abstract |
Objective To analyze the efficacy of quetiapine combined with donepezil in patients with Alzheimers disease. Methods A total of 89 patients with Alzheimers disease were enrolled in our hospital by random number table method. Forty-four patients in the control group were treated with donepezil. In the observation group, 45 patients were treated with quetiapine. The two groups were treated with serotonin (5- HT), norepinephrine (NE), dopamine (DA), cerebrovascular reserve function (CVR), mental behavior symptom score (PANSS), cognitive function score (MMSE), daily living ability (ADL), clinical efficacy and safety. Results After treatment, the BHI, DA, NE, 5-HT, ADL, MMSE scores and total effective rate were higher in the observation group than in the control group, and the NPI score was lower than that in the control group (P<0.05). The incidence of adverse events in the observation group was lower than that in the observation group. Control group (P>0.05). Conclusion Quetiapine combined with donepezil can effectively regulate monoamine neurotransmitter levels in patients with Alzheimers disease, improve cerebral vascular reserve function and mental behavior symptoms, promote cognitive function recovery, improve daily living ability, and have high safety.
|